Skip to main
EKSO

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc. demonstrated a robust recovery in its third-quarter 2025 results, with total revenues reaching $4.22 million, marking a significant 105% increase quarter-over-quarter from $2.06 million in the previous quarter. Additionally, the company reported an improvement in gross margins, rising to 60.3% compared to 39.8% in the second quarter of 2025. The positive sales recovery signals resilience against prior challenges, indicating potential for continued growth, especially in light of the recent non-binding merger agreement with Applied Digital Cloud.

Bears say

The financial analyst notes that Ekso Bionics Holdings experienced a revenue miss in the previous quarter, attributed to order delays in enterprise sales totaling $1.5 million. In the third quarter of 2025, the company reported revenues of $4.23 million and a net loss of $0.54 per share, which, while better than consensus estimates, still indicates ongoing financial challenges. Consequently, the downgrading to a Neutral rating reflects concerns over consistent revenue growth and profitability within the company's operational segments.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.